



#6  
BT  
7-19-02

PATENT

Attorney Docket No.: 8830-14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of Karen Anne Kelso  
Serial No.: 10/030,573  
Filed: January 2, 2002  
For: SEALANT FOR VASCULAR PROTHESES

Group Art Unit 3738

Examiner:

RECEIVED  
JUN 27 2002  
TECHNOLOGY CENTER 1700

INFORMATION DISCLOSURE STATEMENT


RECEIVED  
JUN 24 2002  
TECHNOLOGY CENTER R3700

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37C.F.R. §§1.97-1.98, submitted herewith are copies of the reference listed in the accompanying Form PTO-1449.

The Examiner is respectfully requested to review the items listed on the attached PTO 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.



RECEIVED  
JUN 27 2002  
TC 1700

CERTIFICATE OF MAILING  
UNDER 37 C.F.R. 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231

BY

Werner Rivera

DATE:


June 12, 2002

COPY OF PAPERS  
ORIGINALLY FILED

This Information Disclosure Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

This statement is being submitted before the mailing of an office action. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge Deposit Account No. 50-0573.

Respectfully submitted,



DANIEL A. MONACO  
Registration No. 30,480  
DRINKER BIDDLE & REATH LLP  
One Logan Square  
18th and Cherry Streets  
Philadelphia, PA 19103-6996  
Phone: (215) 988-3312  
Fax: (215) 988-2757  
Attorney for Applicant

COPY OF PAPERS  
ORIGINALLY FILED



SHEET 1 OF 1

SUBSTITUTE FORM PTO-

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
**8830-14**SERIAL NO.:  
**10/030,573****INFORMATION DISCLOSURE CITATION**APPLICANT: **Karen Anne Kelso**FILING DATE: **January 2, 2002**

GROUP

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILED DATE (IF APPROPRIATE)
	AA						
	AB						
	AC						

**RECEIVED**  
JUN 24 2002  
TECHNOLOGY CENTER R3700**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES
	AD						
	AE						

**RECEIVED**  
JUN 27 2002  
TECHNOLOGY CENTER 1700**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	Stauber, D.J., et al.; "Structural Interactions of Fibroblast Growth Factor Receptor With Its Ligands", PNAS, Vol. 97, No. 1, January 4, 2000, pp. 49-54
AG	Gallagher, J.T., "Heparan Sulphates as Membrane Receptors for the Fibroblast Growth Factors", Eur. J. Clin. Chem. Clin. Biochem., Vol. 32, No. 4, 1994, pp. 239-247
AH	Stringer, S.E., et al., "Heparan Sulphate", Int. J. Biochem. Cell Biol., Vol. 29, No. 5, 1997, pp. 709-714.
AI	Green, P.J., et al., "Promiscuity of Fibroblast Growth Factor Receptors", BioEssays, Vol. 18, No. 8, 1996, pp. 639-646
AJ	Coltrini, D., et al., "Different Effects of Mucosal, Bovine Lung and Chemically Modified Heparin on Selected Biological Properties of Basic Fibroblast Growth Factor", Biochem. J. (1994) 303, pp. 583-590.
AK	Belford, D., et al., "Investigation of the Ability of Several Naturally Occurring and Synthetic Polyanions to Bind to and Potentiate the Biological Activity of Acidic Fibroblast Growth Factor", Journal of Cellular Physiology (1993) 157, pp. 184-189.
AL	Hoover, R.L., et al., "Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin, II. In Vitro Studies", Circulation Research (1980) 47, pp. 578-583.
AM	Nissen, N., et al., "Heparin and Heparan Sulphate Protect Basic Fibroblast Growth Factor From Non-Enzymic Glycosylation", Biochem. J. (1999) 338, pp. 637-642.
EXAMINER	DATE CONSIDERED

**COPY OF PAPERS  
ORIGINALLY FILED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.